Bayer starts Phase III trial in non-small cell lung cancer (NSCLC)
- Bayer has enrolled the first patient in the global Phase III SOHO-02 trial for advanced NSCLC with HER2 mutations.
- The trial will compare investigational agent BAY 2927088 to the current standard of care.
- Primary endpoint is progression-free survival (PFS); secondary endpoints include overall response rate (ORR) and duration of response (DoR).
- BAY 2927088 has received Breakthrough Therapy designation from the FDA and China's CDE for second-line treatment in NSCLC.
Read more
OS Therapies announces last patient enrolled in OST-HER2 osteosarcoma phase 2b clinical trial receives last treatment dose
- The last patient in the AOST-2121 clinical trial of OST-HER2 for recurrent, resected osteosarcoma has received their final treatment dose.
- The trial aims to demonstrate efficacy in preventing metastasis, delaying recurrence, and increasing overall survival.
- Topline data readout, including Event Free Survival (EFS) and interim Overall Survival (OS) data, is expected in Q4 2024.
- The trial enrolled 41 patients across 21 sites in the U.S., with primary endpoints of 12-month EFS and 36-month OS.
Read more
HUTCHMED provides update on fruquintinib for second-line gastric cancer in China
- HUTCHMED has withdrawn its supplemental NDA in China for fruquintinib combined with paclitaxel for second-line advanced gastric cancer.
- The decision follows discussions with the NMPA and an internal review indicating the current data package is unlikely to support approval.
- The Phase III FRUTIGA study showed significant improvement in progression-free survival but not in median overall survival.
- HUTCHMED plans to evaluate new pathways for fruquintinib's use in treating gastric cancer.
Read more
Noetik secures $40 million series A financing to advance precision cancer therapies
- Noetik closed an oversubscribed $40 million Series A financing round led by Polaris Partners.
- Funds will be used to expand Noetik's spatial omics-based atlas and CRISPR Perturb-Map platform.
- The investment will also scale training of multi-modal cancer foundation models like OCTO.
- Noetik aims to establish strategic partnerships with academic institutions, healthcare providers, and pharmaceutical companies.
Read more
Kiyatec announces publication of groundbreaking study on 3D Predict Glioma in high-grade glioma patients
- Kiyatec's study in Scientific Reports highlights the impact of the 3D Predict Glioma test on improving survival outcomes for high-grade glioma (HGG) patients.
- The 3D Predict Glioma test can significantly extend progression-free survival and overall survival by accurately predicting patient response to standard chemotherapeutic regimens.
- The study enrolled 102 newly diagnosed HGG patients and found a median progression-free survival increase of 5.8 months and overall survival increase of 7.6 months for responders.
- The test's predictive ability was independent of traditional biomarkers like MGMT promoter methylation, offering a more personalized treatment approach.
Read more
